Pharmasset News

These agents are in different stages of development. One that is further back in the pipeline is Pharmasset's R7128 , a prodrug of the nucleoside analog HCV polymerase inhibitor PSI-6130, which is now in Phase ...

BUYINS.NET: PBKS, RVEP, VRUS, IGPG, WHDCF, EYII Have Also Been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days RDATE:15072008 BUYINS.NET, www.buyins.net, announced today that these select ...

The French National Agency for Research on AIDS and Viral Hepatitis , with the support of Pharmasset, Inc.

Zelos Therapeutics, Inc. announces the appointment of Alan S. Roemer as Chief Financial Officer.

“Our in-house research team has, once again, discovered a new potential product candidate for the treatment of chronic HCV”

Main Category: Liver Disease / Hepatitis Also Included In: Pharma Industry / Biotech Industry Pharmasset, Inc. via MediLexicon

Clean Energy Fuels Corp. posted a loss for the first quarter because contracts the gas provider bought to lock in prices lost a lot of value, the company said Thursday. via Boston Globe

Pharmasset Inc., a clinical-stage pharmaceutical company, said Thursday its first-quarter loss widened on a dip in collaborative payments and higher costs for its hepatitis B program. via Canadian Business Magazine

Pharmasset, Inc. , a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce that it has been selected to ... via Med Ad News

This past weekend concluded the European Association for the Study of the Liver conference, one of the top two annual disease-related conferences. via Fool.com

“Longer-term studies of R7128 with Pegasys plus Copegus are needed to provide additional information about its potential to improve sustained virologic response rates for HCV patients”

Pharmasset Inc. said Friday that R7128 demonstrated "potent short-term antiviral activity and was generally safe and well-tolerated" in a Phase I four-week combination study. via Quamnet

Pharmasset, Inc. announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys plus Copegus in 50 treatment-naive patients chronically infected ... via Med Ad News

“Our pharmacokinetic modeling of the 500mg and 1500mg cohorts of R7128 in combination with Pegasys plus Copegus suggests that the 1000mg dose could deliver a rapid virologic response (RVR) rate similar to the 1500mg dose”

Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 25 Apr 2008 - 0:00 PDT rate article Pharmasset, Inc. via Medical News Today

“Beyond EASL, we expect VRUS will have a relatively quiet year, as both its programs progress. We do not expect major stock-moving catalysts for the remainder of the year, but see 2009 as pivotal.”

Shares of Pharmasset Inc. rose Wednesday, as a UBS analyst upgraded the antiviral drugmaker, citing its low share price and strong hepatitis B and C pipeline. via BusinessWeek

It wasn't the biggest call for cash in the specialty pharma sector, but development-stage drugmaker Pharmasset raised $10 million via a debt financing on Friday. via Fool.com

Posted Mar 11th 2008 10:51AM by Eric Buscemi Filed under: Analyst reports , Analyst initiations MOST NOTEWORTHY: Dreamworks Animation, Pharmasset and Vertex Pharmaceuticals were today's noteworthy initiations: ... via Blogging Stocks

Although it will be slow in the first quarter, 2008 will turn out to be a good year for biotech, especially in the second half. via Biopharm

Shares of Pharmasset Inc. fell Tuesday after a UBS analyst downgraded the stock, saying the value of the company's two most promising drug candidates is now reflected in the share price. via Forbes

Change in Ratings Cephalon CEPH upgraded at Weisel from market-weight to overweight with a $77 price target. via TheStreet.com

BUYINS.NET: IDMI, IDSA, TSEM, UCTT, VMSI, VRUS Have Also Been Added To Naked Short List Today RDATE:15022008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the ... via Customer Interaction Solutions

We've all heard of the "death rattle," the last gasp from a lost soul's lungs. Sometimes, we seem to hear it from the companies in which we invest. via Fool.com